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Early neurophysiological biomarkers and spinal
cord pathology in inherited prion disease
Peter Rudge,1,2 Zane Jaunmuktane,3 Harpreet Hyare,4 Matthew Ellis,5 Martin Koltzenburg,4
John Collinge,2,3 Sebastian Brandner3,5 and Simon Mead2,3
A common presentation of inherited prion disease is Gerstmann-Stra¨ussler-Scheinker syndrome, typically presenting with gait ataxia
and painful dysaesthesiae in the legs evolving over 2–5 years. The most frequent molecular genetic diagnosis is a P102L mutation of
the prion protein gene (PRNP). There is no explanation for why this clinical syndrome is so distinct from Creutzfeldt-Jakob disease,
and biomarkers of the early stages of disease have not been developed. Here we aimed, ﬁrst, at determining if quantitative neuro-
physiological assessments could predict clinical diagnosis or disability and monitor progression and, second, to determine the
neuropathological basis of the initial clinical and neurophysiological ﬁndings. We investigated subjects known to carry the
P102L mutation in the longitudinal observational UK National Prion Monitoring Cohort study, with serial assessments of clinical
features, peripheral nerve conduction, H and F components, threshold tracking and histamine ﬂare and itch response and neuro-
pathological examination in some of those who died. Twenty-three subjects were studied over a period of up to 12 years, including
65 neurophysiological assessments at the same department. Six were symptomatic throughout and six became symptomatic during
the study. Neurophysiological abnormalities were restricted to the lower limbs. In symptomatic patients around the time of, or
shortly after, symptom onset the H-reﬂex was lost. Lower limb thermal thresholds were at ﬂoor/ceiling in some at presentation, in
others thresholds progressively deteriorated. Itch sensation to histamine injection was lost in most symptomatic patients. In six
patients with initial assessments in the asymptomatic stage of the disease, a progressive deterioration in the ability to detect warm
temperatures in the feet was observed prior to clinical diagnosis and the onset of disability. All of these six patients developed
objective abnormalities of either warm or cold sensation prior to the onset of signiﬁcant symptoms or clinical diagnosis. Autopsy
examination in ﬁve patients (including two not followed clinically) showed prion protein in the substantia gelatinosa, spinothalamic
tracts, posterior columns and nuclei and in the neuropil surrounding anterior horn cells. In conclusion, sensory symptoms and loss of
reﬂexes in Gerstmann-Stra¨ussler-Scheinker syndrome can be explained by neuropathological changes in the spinal cord. We conclude
that the sensory symptoms and loss of lower limb reﬂexes in Gerstmann-Stra¨ussler-Scheinker syndrome is due to pathology in the
caudal spinal cord. Neuro-physiological measures become abnormal around the time of symptom onset, prior to diagnosis, and may
be of value for improved early diagnosis and for recruitment and monitoring of progression in clinical trials.
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Introduction
Prion diseases, or transmissible spongiform encephalopa-
thies, are a group of fatal neurodegenerative disorders af-
fecting humans and animals (Collinge, 2001). The central
mechanism of prion diseases is the conversion of host
encoded prion protein (PrPC) to a misfolded multimeric
state (Prusiner, 1982). Human prion diseases occur in spor-
adic, acquired and inherited forms. The majority develop
progressive neurodegeneration with cognitive impairment
and other neurological deﬁcits primarily, but not exclu-
sively, due to CNS dysfunction. Sporadic and acquired
prion diseases generally follow a rapid course lasting less
than 2 years. In some, although not all, hereditary forms
the duration of the disease is much longer ranging from 2
years, to more than 20 years.
Inherited prion diseases are caused by 40 mutations in
the prion protein gene (PRNP) and are highly heteroge-
neous in clinical onset, manifestation and duration, often
with considerable variation within a single family, includ-
ing several examples of a child presenting before the devel-
opment of disease in a parent (Webb et al., 2008). Some
heterogeneity can be explained by the mutation type and by
genetic variation elsewhere in PRNP and some is correlated
with biochemical properties of PrPSc (Parchi et al., 1998;
Kovacs et al., 2002; Mead, 2006; Wadsworth et al., 2006).
In the UK, the P102L mutation is one of the most fre-
quently encountered mutations and has been shown to be
the cause of Gerstmann-Stra¨ussler-Scheinker disease, a term
that has been extended to other mutations (Hsiao et al.,
1989; Bugiani et al., 2000). Patients usually present with
ataxia, especially of gait, and lower limb sensory disturb-
ance in mid-late adulthood. Later cognitive decline occurs
together with multiple CNS symptoms culminating in an
akinetic mute state after a duration of 4 years (Webb
et al., 2008). In this retrospective series (84 patients) with
clinical evidence of weakness and muscle wasting, thought
to be indicative of lower motor neuron dysfunction,
occurred in 22% but nearly all had pyramidal signs; only
one of eight studied neuro-physiologically had evidence of
denervation and 2 of 10 had evidence of large ﬁbre axonal
neuropathy. The sole consistent neurophysiological ﬁnding
was absence of the H reﬂex from tibial nerve stimulation in
the four patients in whom it was sought. Interestingly, ther-
mal threshold testing was abnormal in the lower limbs in
the one patient tested. Further neurophysiological studies
have been reported in seven patients (Salsano et al.,
2011). The only abnormality in this series was a loss of
the H reﬂex in the lower limbs in the four who were tested
reﬂecting the areﬂexia. Large ﬁbre peripheral conduction in
motor and sensory nerves and somatosensory evoked po-
tentials were normal. Based on these neurophysiological
studies, an imaging study (Arata et al., 2006) and a
single morphological case study (Yamada et al., 1999), a
caudal myelopathic process as an underlying cause of are-
ﬂexia and sensory loss in patients with Gerstmann-
Stra¨ussler-Scheinker disease due to PRNP P102L mutation
has been proposed. However, detailed conﬁrmatory mor-
phological studies in a case series, regarding the extent and
distribution of the underlying pathology have not been
done.
Here we report the prospective longitudinal clinical and
neurophysiological ﬁndings in 23 patients carrying the
P102L mutation, including the development of symptom
onset, diagnosis and disability in six and autopsy in ﬁve.
The patients are members of the large UK pedigrees which
we have followed for over 20 years (Webb et al., 2008).
There were two objectives of this study. First, to determine
if alterations in neurophysiological parameters predict the
onset of clinical disease. The development of such measures
is important since potential treatments, including those
being produced for prion diseases, are likely to be more
effective if given before extensive neuronal damage has
occurred. In other inherited neurodegenerative diseases pre-
diction of clinical onset has relied on family history
(Alzheimer’s disease) or length of DNA repeat regions
(Huntington’s disease). The situation is even more difﬁcult
in the inherited prion diseases because age at onset vari-
ation is high (onset for the P102L associated syndrome in
the pedigree we studied ranges from ages 26 to 71, stand-
ard deviation 10 years), and criteria are not optimized for
an early diagnosis. Current criteria for diagnosis of in-
herited prion diseases were designed for epidemiological
purposes and require a 6-month history of an progressive
neuropsychiatric syndrome (NCJDRSU, 2017). Inherited
prion disease due to a P102L mutation is well suited to
develop neurophysiological biomarkers as patients appear
to present with lower limb areﬂexia and sensory disturb-
ance before any signiﬁcant neurological impairment occurs.
Further, serial neuro-physiological parameters might be a
valuable objective marker of disease progression during
therapeutic trials. Our second objective was to correlate
the clinical and neurophysiological ﬁndings with neuro-
pathological abnormalities. In particular, we aimed at
understanding the cause of the areﬂexia and sensory loss
and how this could be matched with the anatomy of prion
protein deposition and neurodegeneration in the peripheral
and spinal tracts.
Materials and methods
Patient cohort and clinical
assessment
The National Prion Monitoring Cohort Study (Cohort Study)
was established in 2008 and is an observational longitudinal
study of patients with, or at risk of, developing human prion
disease (sporadic, acquired and inherited prion diseases)
(Thompson et al., 2013). All eligible patients referred to the
National Prion Clinic (NPC) are invited to take part in the
Cohort Study, which involves review by a NPC consultant
neurologist or clinical research fellow and collection of
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systematic clinical data including physical examination ﬁnd-
ings, blood tests, neuropsychology, neurophysiology and
MRI at regular intervals depending on the type of prion dis-
ease. In the case of P102L inherited prion disease, the interval
would typically be 12 months in asymptomatic mutation car-
riers and 6 months in symptomatic disease. Systematic history
taking, rating scale analysis and review of clinical letters
deﬁned three milestones: (i) onset of any symptom that subse-
quently developed into part of the Gerstmann-Stra¨ussler-
Scheinker syndrome; (ii) onset of disability, deﬁned as an
MRC Prion Disease Rating Scale score 520; and (iii) the
time at which the NPC clinician conﬁrmed the diagnosis of
Gerstmann-Stra¨ussler-Scheinker with patient and family. The
deﬁnition of (i) is complicated because gene mutation carriers
have frequent, non-progressive psychological/psychiatric
comorbidities long before clinical onset; however, psychiatric
symptoms can be a presenting feature of Gerstmann-Stra¨ussler-
Scheinker (Thompson et al., 2014).
Molecular genetics
From the Cohort Study of 31 patients at risk of carrying the
mutation, 23 were sequenced for PRNP (Wadsworth et al.,
2017). Informed consent for the analysis was obtained in all
cases. PRNP includes a common nucleotide polymorphism in
European populations which encodes for either methionine or
valine at codon 129; the genotype at this position was deter-
mined as part of sequencing the PRNP open reading frame.
MRI analysis
MRI studies performed at either 1.5 or 3 T were reviewed. The
images were reviewed by a consultant neuro-radiologist (H.H.)
and a consultant neurologist (P.R.), both with 9 years’ experi-
ence in prion disease imaging, and agreement was achieved via
consensus. Signal abnormality was assessed in the caudate,
putamen and thalamus on T2-weighted, FLAIR and/or diffu-
sion-weighted imaging (DWI) sequences. Cortical signal abnor-
mality was assessed on DWI sequences where available in the
following areas: frontal, parietal, temporal, occipital, cingulate,
insula, hippocampus and cerebellum. Finally the T1-weighted
images were reviewed for either focal or generalized supra-
tentorial and/or cerebellar atrophy.
Neurophysiological studies
Standard nerve conduction studies (Preston, 2013) were per-
formed on a Nicolet Viking Select (Natus) with temperatures
430 and 32 in upper and lower limbs respectively. Motor
nerve conduction studies and F-waves were recorded as base-
line to negative peak using the belly tendon montage and a
terminal conduction distance of 80mm. Sensory responses
were recorded antidromically from the sural (retromalleolarly)
and the superﬁcial peroneal nerve at a conduction distance of
120mm and orthodromiclly between the base of digits 2, 3
and 5 to the median or ulnar nerve at the wrist. For recording
of the H-responses the patient was prone or in the lateral
position with the knee ﬂexed at 30 and asked to clench
teeth and ﬁsts. M- and H-responses were recorded from the
calf muscles following graded electrical stimulation at the mid-
point of the back of the knee using a stimulus duration of
1ms. The magnitude of the reﬂex response was expressed as
the ratio H/M amplitude measured peak to peak.
Thermal thresholds were recorded using a TSA-II (Medoc,
Ltd.) and a 30  30mm thermode placed on the lateral
dorsum of the foot or hand. The tests were performed using
the method of limits with a baseline of 32C, a change of
temperature of 1C, and upper and lower limits of 55C and
0C, respectively. Thresholds were deﬁned as the average of
three trials for cold (CDT) and warm (WDT) detection thresh-
olds. The sequence of testing was CDT, WDT in hands and
feet (Rolke et al., 2006).
Itch and neurogenic ﬂare were evoked by the intracutaneous
injection of 10 ml of 100 mg histamine chloride into the anterior
aspect of the lower leg. The magnitude of the maximal itch
sensation was scored on a 0–10 Likert scale. The ﬂare was
studied in a 10  10 cm area (1  1mm pixel, scan duration
5 min) with a Laser Doppler Imager (moorLDI, Millwey).
The area of the ﬂare was expressed as the area of pixels ex-
ceeding the mean + 3 (rather than 2 as described by Bickel
et al., 2002) standard deviations of the baseline.
Neuropathological examination
Neuropathological studies were carried out on 3 of 11 symp-
tomatic patients and on two additional P102L Gerstmann-
Stra¨ussler-Scheinker patients not included in the neurophysio-
logical study. The brains, including the lower brainstem were
removed in all ﬁve, the spinal cord of variable length in three
and representative peripheral nerves in two patients. The
sampled nerves were ﬁxed in 10% buffered formalin for 1
week and the brainstem together with the spinal cords contin-
ued to be ﬁxed for another 2 weeks. Then brains and spinal
cords were sliced in coronal and transverse sections, respect-
ively. Parafﬁn wax sections of 4-mm thickness were prepared
and stained with haematoxylin and eosin and 14-mm thick
sections were stained with Luxol fast blue/cresyl violet.
Immunostaining for abnormal prion protein was carried out
on 4-mm thick sections with anti-PrP ICSM35 (1:1000 of
100 mg/ml solution, D-Gen Ltd) and 12F10 (1:200 Cayman
Chemical). ICSM35 recognizes residues 93–102, and is
known not to bind to P102L mutant PrP, but does recognize
PrP derived from the wild-type allele (Wadsworth et al., 2006).
12F10 labels residues 142–160 of both wild-type human PrP
and P102L PrP. To detect abnormal PrP deposits, deparafﬁ-
nized sections were treated with 98% formic acid for 5min,
placed on an automated Ventana Discovery XT staining ma-
chine, and treated with Cell Conditioning Solution Plus and
Protease 3, incubated in Superblock for 10min, then exposed
to the primary antibody followed by biotinylated anti-mouse
IgG secondary antibody and visualised using the DAB Map
Detection Kit (Ventana Medical System). Sections were coun-
terstained with haematoxylin and coverslipped (LEICA
CV5030 coverslipper). All stainings were carried out with ap-
propriate controls.
Evaluation of the abnormal prion
protein deposits
In each case where tissue was available the pattern of the ab-
normal prion protein deposits (ﬁlamentous, granular or
plaque-like) and the regional distribution of the prion
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pathology were assessed with particular emphasis on the fol-
lowing areas: spinal grey matter, spinothalamic pathway, pos-
terior column-medial lemniscus pathway (PCML), anterior and
posterior nerve roots, nerve roots in the cauda equina, periph-
eral nerves.
Image capturing and analysis
For image capturing all histological slides were digitalized on a
LEICA SCN400 scanner (LEICA UK) at 40 magniﬁcation
and 65% image compression setting. For assessment of the
density of abnormal prion protein deposits on histological
slides from the brainstem medulla at the level of gracile and
cuneate nuclei digital image analysis was conducted using
Deﬁniens Tissue Studio 3.6 (Deﬁniens). Regions of interest—
gracile and cuneate nuclei—were selected manually in each
case. Tissue Studio composer actions were used to automatic-
ally identify regions of interest. In each case the size of the
region of interest and the intensity of the prion labelling was
calculated and further compared between both nuclei.
Ethics approval
Research ethics approval was obtained from Scotland MREC
A. Informed consent to use the tissue for research was ob-
tained in all instances.
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Results
Thirty-one patients with or at risk of inheriting the P102L
mutation were recruited; 23 patients (16 female) with the
mutation were studied neuro-physiologically. One gene mu-
tation positive patient had a diabetic neuropathy poten-
tially confounding the neurophysiological assessment and
eight at risk of having the mutation were not genotyped.
Sixteen patients were asymptomatic and six symptomatic
when ﬁrst seen. Six patients became symptomatic during
follow up. At the start of the study the mean age of the
symptomatic patients was 49.3 years (range 26–61) and the
asymptomatic patients was 41.6 years (range 28–56). The
maximum number of neurophysiological studies in any one
patient was ﬁve over a period of up to 10 years.
Genetic results
Thirteen patients with the mutation were codon 129 me-
thionine homozygous, eight of whom were symptomatic at
some stage during the study; eight were heterozygotes,
three of whom were symptomatic at some time during
the study; and in one patient the polymorphism at codon
129 is unknown.
Clinical assessment
Patients symptomatic on presentation
The presenting symptoms in the symptomatic patients were
predominantly ataxia of gait and pain or discomfort in the
lower limbs. Myoclonus, cognitive decline and weakness
were less prominent except in the youngest patient who
presented with severe cognitive decline. At subsequent
follow-up there was progression of pain or itching in
legs, ataxia, myoclonus and cognitive decline to varying
degrees (Webb et al., 2008).
The ﬁndings on clinical examination at the ﬁrst visit in
those who were initially symptomatic, 1–18 months after
ﬁrst developing symptoms, are summarized in Table 1.
Upper limb examination was initially normal in all. The
neurological signs progressively worsened during follow-
up and new signs developed, including myoclonus, cogni-
tive decline and weakness (Table 1). Late in the course of
the disease abnormal neurological signs developed in the
upper limbs with loss of the tendon reﬂexes and muscle
wasting; at this stage detailed sensory assessment was not
possible because of cognitive decline. Five patients have
died at 35–56 (mean 46.6) months after developing
symptoms.
Patients who converted from asymptomatic to
symptomatic
Six patients became symptomatic at a mean age of 49.6
years (range 42–58) while under review in the Cohort
study; diagnosis was conﬁrmed at an average 11.8
months later, and after a further average 5.7 months, the
symptoms become signiﬁcant in that they affected activities
of daily living. The last examination before becoming
symptomatic had been normal in ﬁve patients; the other,
who had a parietal meningioma removed some years
before, had an extensor plantar response and minor loss
of vibration appreciation in the leg. The six patients were
examined 3 to 6 months after ﬁrst developing symptoms all
of whom complained of feeling unsteady and three of lower
limb dysaesthesiae. Examination at that time is summarized
in Fig. 1D. No patients had abnormal neurological signs in
the upper limbs at the time they ﬁrst developed symptoms.
The proportion of patients exhibiting these abnormal signs
increased after conversion (Fig. 1D). Two patients died 49
and 72 months after becoming symptomatic during which
time they developed pyramidal weakness greater in the
lower limbs, increasing ataxia, sensory loss, incontinence
and cognitive decline ultimately becoming akinetic and
mute.
Patients who were asymptomatic throughout study
Of the 11 patients in this group one had absent lower limb
reﬂexes. No neurological signs were elicited in the other 10
patients.
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Figure 1 Neurophysiological and clinical findings in patients who became symptomatic. Serial measurement of cold threshold (A),
hot threshold (B) and H reflex latency (C). Time of significant symptom onset (MRC Scale score520) is indicated by dark grey shading at time 0.
Time of first symptom is indicated in individual patients by a change from dashed to solid line, and from the time of first symptom in any patient
with light grey shading. Months prior to significant symptoms shown as negative values; months after significant symptoms shown as positive
values. Black lines are serial measurements of five cases symptomatic when first seen. Horizontal grey lines in A and B are 95% confidence
measurement for thermal thresholds. Coloured lines are serial measurements in patients who converted during study: Case 1 red, Case 2 blue,
Case 3 green, Case 4 brown, Case 5 purple, Case 6 orange. (D) Serial clinical findings prior to symptomatic conversion (negative values) and after
conversion (positive values). Conversion indicated by broken line at time 0. Normal findings indicated in blue, abnormal findings in red, and no
assessment in black. Spinothalamic refers to detection of cold or pain in lower limb, vibration refers to detection of vibration at the ankle, reflexes
refers to ankle tendon reflex, ataxia refers to gait ataxia, and Babinski refers to plantar response. (E) Segmented linear model of thermal
thresholds assuming no change 30 months prior to change of threshold followed by linear deterioration thereafter. R2 = 0.62, P5 104.
Table 1 Summary of clinical findings at first and final examination in patients who were symptomatic when referred
Time Weakness Myoclonus Absent reflex Extensor plantar Vibration loss Thermal loss Ataxia Cognitive decline
First 1/5 2/6 5/6 3/6 3/6 4/5 6/6 3/6
Last 3/5 5/6 6/6 4/5 5/6 5/5 5/5 6/6
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Imaging
Serial MRIs of the brain were obtained in 11 patients who
were symptomatic at some time during the study, one of
whom also had an MRI of the spine; two to ﬁve studies
were performed in all of these patients. Signal abnormality
in the cerebral cortex was detected in two patients and in
the basal ganglia in one patient, 6 and 7 months after de-
veloping symptoms. Cortical and cerebellar atrophy was
detected in six. In all cases these changes were observed
after symptom onset. The one spine MRI was normal.
Neurophysiological results
All studies in the upper limbs were normal. In the lower
limbs sensory and motor conduction, F wave, histamine
ﬂare and threshold tracking were normal in all patients in
whom the test was done.
Abnormalities in patients who were
symptomatic on entry to the study
The H reﬂex was normal in three of ﬁve patients when ﬁrst
assessed at 7–17 months after symptom onset and was ab-
normal in all by 41 months. Similarly, thermal thresholds
were normal or borderline in three patients initially but
were abnormal in all 10–41 months after ﬁrst developing
symptoms (Fig. 1). Histamine-induced itch, which was not
consistently assessed, was abnormal in all patients 8–41
months after symptom onset.
Findings in patients who became
symptomatic
Six patients who were asymptomatic when ﬁrst seen de-
veloped symptoms of the disease during follow-up.
Symptom onset was deﬁned as the time at which any symp-
tom developed that subsequently progressed and was
retrospectively thought to be part of the Gerstmann-
Stra¨ussler-Scheinker syndrome. These six patients devel-
oped signiﬁcant symptoms affecting normal daily activities
(disability onset) between 3 and 30 months after symptom
onset [mean = 17.5 months, standard deviation (SD) = 9.6]
and were conﬁrmed by their consultant as having de-
veloped the disease between 3 and 18 months after symp-
tom onset (mean = 11.8, SD = 7.2). Changes in
neurophysiological parameters are shown relative to the
onset of signiﬁcant symptoms in the charts (Fig. 1).
The H reﬂexes were normal in all patients prior to symp-
tom onset and were lost in four patients 3–14 months later,
in all four cases prior to or at the same time as clinical
diagnosis and/or the development of disability; in the other
patients the H reﬂex was obtained when last measured 4
and 30 months after conversion (Fig. 1C).
Threshold for detection of hot was normal (544C),
except on one occasion, in all patients before symptom
onset. Cold threshold was below 23C in one patient 6
months before developing symptoms and normal in the
rest. When seen 3–14 months after symptom onset, and
prior to onset of signiﬁcant symptoms, or clinical diagnosis,
all patients had abnormality of thermal sensation; in four
both hot and cold thresholds were abnormal, and in the
other two only one modality was abnormal (Fig. 1A and
B). Average hot threshold was 37.7C in the last examin-
ation prior to symptom onset, and 45.0C in the following
examination prior to clinical diagnosis and disability onset
(n = 6, SD = 1.43, paired t-test versus previous examination,
P = 0.0012). A striking feature was the change in threshold
after symptom onset; in the case of hot threshold the
change was of the order of 5–8C and cold detection was
lost in all but one case within 30 months.
When thermal threshold changes from baseline were
examined in patients who converted using a range of
linear and non-linear statistical models, the best ﬁt
(R2 = 0.62) was observed with a segmented linear model.
This model assumed no change in thermal thresholds
(slope = 0) until 30 months prior to symptom onset, fol-
lowed by linear deterioration (Pearson correlation
P5 0.0001, 2.9C/year, 95% 1.8–4.0C/year; Fig. 1E).
Itch was not consistently determined. However, three pa-
tients had lost this sensation when assessed at 22–27
months after symptom onset and two still reported itch
when last assessed at 15 and 16 months after symptom
onset. One patient with the shortest follow-up period fol-
lowing conversion was not tested but had experienced this
sensation on histamine injection before. The histamine ﬂare
was normal in all.
Findings in persistently asympto-
matic subjects
There were neurophysiological abnormalities in three
asymptomatic patients aged 42–48 years. Two had an
absent H reﬂex in the lower limbs and two had abnormal
thermal detection thresholds including one of those with
abnormal H reﬂexes. Two of these patients did not detect
an itching sensation with histamine injection. Serial meas-
urements of thermal thresholds over a period of up to 61
months showed no consistent change with small variation
between measurements greater for hot (9%) than cold
(55%). Similarly, in those patients with an H reﬂex
there was a small variation between measurements of
510% but no trend. Average cold threshold was 28.2C
(n = 19 assessments, 11 patients, SD = 2.2), average hot
threshold was 37.0C (SD = 3.7) and H latency was
26.9ms (SD = 7.3) (Fig. 1).
Neuropathological results
Abnormal prion protein deposits were detected with both
12F10 and ICSM35 (data not shown) antibodies. Generally
12F10 showed more prominent labelling, resulting in a more
widespread and dense abnormal prion protein staining and
importantly, also in a wider range of labelling patterns.
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There was variability in the labelling intensity between the
cases, in that an increase of the post mortem formalin ﬁxation
interval attenuated immunostaining intensity.
PrP deposits in the sensory pathway
In the posterior nerve roots, in the immediate vicinity to the
spinal cord, occasional labelling in the unmyelinated and
pauci-myelinated areas was evident at the sacral level. In
the spinothalamic pathways, dense labelling was seen in the
Lissauer’s tract and marginal nucleus of the spinal cord
(lamina 1), substantia gelatinosa (lamina 2, termination of
C ﬁbres), nucleus proprius (lamina 3 and 4 , major termin-
ation of A ﬁbres), dorsal nucleus in thoracic and high
lumbar cord (lamina 5 and 6), and central white commis-
sure (lamina 10) comprising crossing ﬁbres of the spinotha-
lamic pathway (Fig. 2). In the white matter tracts
occasional ring-like deposits were detected along the
whole length of the spinothalamic pathway.
The posterior column-medial lemniscus pathway showed
only rare deposits in the white matter tracts, while the gracile
and the cuneate nuclei showed dense abnormal PrP deposits
(Fig. 3). These results in two patients were conﬁrmed using
a quantitative histological imaging system (Deﬁniens
Developer). In one patient the gracile nucleus was more af-
fected than the cuneate whilst no difference in the labelling
intensity and coverage on quantitative assessment was
observed in the other patient (Fig. 3B). In Clarke’s (dorsal)
nucleus (lamina 5 and 6) labelling was prominent (Fig. 2H
and I) and peri-neuronal labelling was seen around the large
motor neurones and small interneurons within the anterior
horns (Fig. 2O). The thalamus contained frequent synaptic
deposits and plaques of various sizes.
In the neocortical areas, including parietal cortex, prion
pathology was widespread and similar to that reported pre-
viously (Webb et al., 2008). No deﬁnite prion pathology
was seen in the anterior nerve roots of the cauda equina or
in the peripheral nerves (median, sural and ulnar nerves in
two patients, sciatic in one and radial in another patient).
Discussion
There is a reasonable expectation that treatments for neu-
rodegenerative diseases may be ineffective unless given in
the earliest stages of disease before substantial neuronal
damage has occurred. This motivation has led to increased
interest in monogenetic forms of dementia in which indi-
viduals at high-risk of disease can be identiﬁed, studied and
potentially treated prior to or soon after symptom onset
(Tabrizi et al., 2009). To achieve this, it is necessary to
develop biomarkers that are abnormal in symptomatic pa-
tients carrying the relevant mutation then to follow a suf-
ﬁciently large cohort of patients with the mutation from the
asymptomatic to the symptomatic phase to determine when
the biomarker becomes abnormal and therefore determine
if it predicts disease milestones. In this paper we have
shown that neurophysiological abnormalities predate the
clinical diagnosis and disability in inherited prion diseases
due to a mutation in the prion protein gene (P102L) in
which ataxia of gait, lower limb areﬂexia and lower limb
sensory changes are the usual initial ﬁndings; further, these
measures may be of value in monitoring disease progres-
sion. We also describe the pathological basis for these clin-
ical and neuro-physiological ﬁndings in a subset of patients.
The ﬁrst objective in this study was to determine if
neurophysiological testing of thermal sensation and H
reﬂex, being more objective and quantiﬁable than the
usual clinical examination, is of value in predicting clinical
milestones in Gerstmann-Stra¨ussler-Scheinker disease due to
P102L. The progression of Gerstmann-Stra¨ussler-Scheinker
disease passes from asymptomatic through clinical stages,
with initial symptoms often being non-speciﬁc (tingling in
the feet, alteration in mood, personality or gait), and only
later are the symptoms and signs clear enough for clinical
diagnosis, and/or severe enough to impair activities of daily
living. Neurophysiological measurement of thermal thresh-
old and the H reﬂex did not predict the earliest milestone
of symptom onset in individual cases, but became abnormal
shortly thereafter, and predated clinical diagnosis and the
development of disability. Regression analyses of groups of
patients converting to clinical disease suggested that the
warm detection threshold in the legs starts to change 3
years before signiﬁcant (disabling) symptoms are present.
The most immediate implication of our observations is
for a proximity biomarker in Gerstmann-Stra¨ussler-
Scheinker disease: a new abnormality of the hot or cold
lower limb thermal threshold or the H reﬂex predicts clin-
ical diagnosis and could support early recruitment to clin-
ical trials through eligibility criteria.
In prion diseases, a special complexity is that age at clin-
ical presentation may extend across an adult lifespan, and
the clinical features at presentation are heterogeneous be-
tween and within families (Mead, 2006). This means that
estimates of age at clinical onset are highly unreliable
(standard deviation of age of clinical onset typically 10
years for inherited prion diseases). A limitation of our work
is the relatively small number of participants who con-
verted to clinical disease during the study. On the other
hand, an advantage of our study is the fact that clinical
milestones were observed and not estimated. Large multi-
national studies of monogenetic causes of dementia e.g.
DIAN and GENFI, use predictions of clinical onset to
allow inference of biomarker change prior to symptom
onset (Bateman et al., 2012; Rohrer et al., 2015; Ryan
et al., 2016). Differences between estimated and measured
clinical onset may lead to an overestimate of how early
biomarker change occurs. It is notable that the biomarker
changes reported in this study are much closer to clinical
onset than was estimated in these related neurodegenerative
disorders.
An additional objective was to see if there was increase in
the magnitude and number of abnormalities on neuro-
physiological testing once the patient was symptomatic.
Unfortunately the H reﬂex, which is dependent on the A
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Figure 2 Prion protein pathology in the spinal cord and brainstem of a representative patient with a PRNP P102L mutation.
(A–E) Schematic demonstration of the extent and distribution of the prion protein pathology in the spinothalamic pathway (dark blue: 1 Lissauer’s
tract, 2 substantia gelatinosa Rolandi, 3 nucleus propius, 4 spinothalamic decussation, 5a lateral spinothalamic tract, 5b anterior spinothalamic
tract), Clarke’s (dorsal) column (green 6) and posterior column-medial lemniscus pathway (light blue; 7 posterior columns, 8 medial lemniscus).
(F–O) Immunostaining for the abnormal prion protein with 12F10 antibody: Overview of the abnormal prion protein deposits within the spinal
cord and brainstem (F–J). In the brainstem (F–G) the prion pathology is seen with widespread distribution and is not restricted to the sensory
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afferent nerve ﬁbres, was suddenly lost with no evidence of
a gradual increase in latency. This bimodal distribution is
explained by the narrow range of velocities in these A
ﬁbres which results in the sudden loss of the response
rather than a gradual change. An attempt was made to
overcome this limitation by calculating the ratio of the
amplitude of the H reﬂex to the primary muscle response
(M) but this was extremely variable within a subject and
was not reliable. In contrast thermal thresholds, although
dependent on the subject reporting the onset of sensation,
gives an absolute measurement of thresholds. In the present
study, in spite of the limited number of patients studied,
hot thermal thresholds did sequentially decline in all and
might be useful as an objective measure of change in clin-
ical trials. Thermal thresholds might be included as a sec-
ondary endpoint in clinical trials, testing for a change in
slope of deterioration over time compared with controls.
We have not studied enough patients to estimate the po-
tential power of such a biomarker. The H reﬂex would be
less attractive because of its binary outcome. In conclusion,
the present study provides proof of principle that neuro-
physiological assessments (particularly the hot thermal
threshold) might be of value in monitoring transition and
progression of Gerstmann-Stra¨ussler-Scheinker disease due
to P102L mutation but a larger cohort of patients, with a
prospectively deﬁned biomarker will be required to deter-
mine the conﬁdence intervals of the different parameters
studied.
A second objective was to delineate the anatomical basis
for the symptoms and investigation ﬁndings in this study.
The present study showed no evidence of abnormal periph-
eral nerve dysfunction. The loss of the H reﬂex is consistent
with damage proximal to the dorsal root ganglion or
within the lumbar spinal cord involving the A afferent
pathway to the anterior horn cells; an earlier study came
to the same conclusion (Salsano et al., 2011). The abnor-
mal thermal detection thresholds indicate an abnormality in
the spinothalamic pathways between the periphery and the
cerebral cortex; peripheral cold detection is dependent on
A ﬁbres while hot detection is mediated by C ﬁbres
(Fowler et al., 1988). The abnormality detected in the
lower limbs were unlikely to be due to involvement of
the peripheral pathway as the histamine ﬂare response, de-
pendent on non-mechanoreceptor C ﬁbres, was intact in
those patients who did not report itching to histamine in-
jection, a sensation also dependent on the same group of
ﬁbres (Aronin et al., 1987). This indicates damage to the
spinothalamic system within the CNS between the substan-
tia gelatinosa and thalamus. Finally, the abnormality of
vibration sense appreciation on clinical examination implies
damage to the A afferents passing through the posterior
columns to the posterior column nuclei.
The neuropathological ﬁndings largely conﬁrmed these
predictions. Dense synaptic deposits of abnormal prion
protein were identiﬁed in the posterior horns of the lumbo-
sacral spinal cord, in keeping with a previous case report
(Yamada et al., 1999). However, in our study PrPSc depos-
ition was more widespread; deposits were identiﬁed in
Clarke’s column (nucleus dorsalis), and the posterior
column nuclei, with some deposition in the spinothalamic
tracts and dorsal columns. In addition there was peri-neur-
onal labelling around the large motor neurons and small
interneurons within the anterior horns. Interestingly, prion
protein deposits were present not only in the lumbosacral
cord but in the same areas also in the thoracic and upper
cervical cord but these changes probably reﬂect a late de-
velopment given the normal neurophysiology in the upper
limbs in the early stages of the disease.
These neuropathological ﬁndings in the lumbosacral cord
are a sufﬁcient explanation of the neurophysiological
abnormalities in the lower limbs. The prion protein depos-
ition in the substantia gelatinosa, spinothalamic tracts and,
to a lesser extent, in the small myelinated (A) ﬁbres in the
lateral part of the proximal dorsal roots explains the ab-
normal thermal thresholds and loss of itch sensation, while
the abnormality in the posterior column nuclei explains the
impaired vibration sensation. The H reﬂex abnormality
could reﬂect either impaired conduction in the A ﬁbres
passing through the affected area of the neuropil in the
dorsal horn or involvement of the motor neurones.
Similarly, the late development of leg weakness could be
due to anterior horn cell loss in the lumbar region. The
early development of ataxia of gait has been traditionally
explained by cerebellar involvement in Gerstmann-
Stra¨ussler-Scheinker disease, but the extensive deposition
of PrPSc in Clarke’s column where collaterals of the A
ﬁbres terminate, the cells of which are not found in the
cervical cord, could well be the proximate cause of the
unsteadiness; such an explanation would also account for
the relatively preserved limb coordination during the initial
course of the disease.
12F10 antibody revealed more extensive pathology when
compared with ﬁndings seen using ICSM35 antibody. Less
prominent, albeit not complete absence of labelling of the
abnormal prion protein using ICSM35 antibody, can be ex-
plained by previously shown inability of ICSM35 to recog-
nize human abnormal prion protein with lysine at position
102 and the documented spectrum of PrP wild-type
Figure 2 Continued
pathways. At all levels of the spinothalamic pathway there is dense synaptic labelling (K–L) in the Lissauer’s tract, marginal nucleus of the spinal
cord (lamina 1), substantia gelatinosa (lamina 2), nucleus proprius (lamina 3/4), lamina 5 and 6, central white commissure and Clarke’s (dorsal)
nucleus. In the substantia gelatinosa in addition to synaptic labelling there are occasional small plaques (M). In the white matter tracts of the
spinothalamic and posterior column-medial lemniscus pathway there are occasional circular intra-myelin inclusions (N, arrowhead). In the
anterior horns there is occasional peri-neuronal labelling around the large motor neurons and small interneurons (O). Scale bar = 50mm in K–O.
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involvement with subsequent conformation to PrPSc in the
disease process (Wadsworth et al., 2006). Prolonged post-
mortem interval, long formalin ﬁxation time and the selec-
tion of the antibodies are plausible explanations for com-
pletely negative labelling for the abnormal prion protein in
the spinal cord in two Gerstmann-Stra¨ussler-Scheinker cases
described in another study (Lee et al., 2005).
Conclusion
This study shows that the initial symptoms and signs in
most cases of Gerstmann-Stra¨ussler-Scheinker disease are
likely to be due to abnormal prion protein deposition
within the lumbosacral cord and the posterior column
nuclei. Neurophysiological assessment did not predict the
onset of the initial symptoms of the disease but predated
signiﬁcantly disabling symptoms and clinical diagnosis, and
subsequently progressively deteriorated, therefore may be
of value as an early biomarker.
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Figure 3 Prion protein pathology in the gracile and cuneate nuclei. In four patients there are widespread abnormal prion protein
deposits in both nuclei with no difference in the labelling intensity and coverage when assessed quantitatively in three patients (A, shown one
representative case). In one patient (B) quantitative assessment confirms that the gracile nucleus (purple in cartoon) is more affected than the
cuneate nucleus (yellow in cartoon). Luxol fast blue/cresyl violet stain above, 21F10 antibody stain below.
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